Evidence map›Paper›PMID 20425006›Full record

ReviewCurrent allergy and asthma reports2010

Inflammasome and IL-1beta-mediated disorders.

Hal M Hoffman, Alan A Wanderer

Abstract readReview
In one paragraph

Review in Current allergy and asthma reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. A novel functionalFrontiers in immunology · 2024
    Article
  12. Article
  13. The inflammasome in biomaterial-driven immunomodulation.Journal of tissue engineering and regenerative medicine · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Screening for the Active Anti-Inflammatory and Antioxidant Polyphenols ofInternational journal of molecular sciences · 2021
    Article
  18. Article
  19. Review
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hal M HoffmanDivision of Allergy and Immunology, University of California at San Diego and Rady Children's Hospital of San Diego, La Jolla, CA 92093, USA. hahoffman@ucsd.edu
Alan A Wanderer

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The NLRP3 inflammasome is an intracellular complex that regulates the release of proinflammatory cytokines such as interleukin-1beta in response to exogenous pathogens and endogenous danger signals. Evidence from studies involving human genetics, human ex vivo mononuclear cell responses, and in vivo and in vitro murine models confirms the importance of the inflammasome and interleukin-1beta in the pathogenesis of several inherited and complex diseases. The availability of several effective interleukin-1beta targeted therapies has allowed for successful proof-of-concept studies in several of these disorders. However, many other diseases are likely to be mediated by the inflammasome and interleukin-1beta, providing additional targets in the future.

Indexed as

AnimalsAsbestosisCarrier ProteinsCryopyrin-Associated Periodic SyndromesDiabetes Mellitus, Type 2GoutHumansInflammationInterleukin-1betaLung DiseasesMiceNLR Family, Pyrin Domain-Containing 3 ProteinSilicosisCarrier ProteinsInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, human

Identifiers

PMID20425006
PMCPMC2892083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.